One of the central ambitions in cancer immunotherapy is sustaining the killing power of CD8+ T cells long enough to defeat tumors and chronic infections. A receptor called A2AR has long been targeted for blockade on the assumption that removing its immunosuppressive brake would reinvigorate exhausted T cells — but this new work from PNAS reveals that assumption may be fundamentally flawed, with consequences for a generation of drug development programs.
Using A2AR-eGFP reporter mice combined with single-cell multiomics, researchers mapped how A2AR behaves across the full arc of CD8+ T cell differentiation during chronic viral infection and tumor challenge. TCR stimulation rapidly induced A2AR expression, which then persisted under chronic antigen exposure and hypoxia. Sustained A2AR signaling drove terminal exhaustion through the canonical Gαs-cAMP-PKA pathway. But the paradox emerged when A2AR was genetically deleted: rather than rescuing T cell function, its loss accelerated differentiation toward the terminally exhausted state. Mechanistically, A2AR deficiency activated CD122 (IL-2Rβ)-dependent signaling, and genetic deletion of CD122 in A2AR-knockout cells partially reversed this accelerated exhaustion, pinpointing an unexpected compensatory axis.
This finding challenges a core tenet underlying several clinical-stage A2AR antagonists, including compounds tested in combination with PD-1 checkpoint inhibitors. The field assumed that adenosine-axis blockade would be unambiguously immunostimulatory; this work suggests the relationship is non-linear and context-dependent. The IL-2Rβ connection is particularly noteworthy: IL-2 signaling is already a heavily explored therapeutic lever in immuno-oncology, and discovering it as a downstream mediator of A2AR loss creates both a complication and a potential combination target. Limitations include the exclusive use of murine models, meaning human T cell biology — which differs meaningfully in exhaustion circuitry — remains to be tested. Still, the mechanistic granularity here is substantial, and the finding is potentially paradigm-shifting for adenosine-axis drug design.